{"success":true,"data":{"pressRelease":{"id":"130183","rtpr_id":"nGNX3k6hRW","ticker":"CAPR","exchange":"NASDAQ","all_tickers":["CAPR"],"title":"Investor Notice: Capricor Therapeutics (NASDAQ:CAPR) Accused of Misleading Investors in Securities Fraud Class Action – Contact BFA Law if You Lost Money","author":"Globe Newswire","published_at":"2026-08-28T10:46:00.134Z","article_body":"NEW YORK, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=lFM_FrqgjWD9sSl_oHO13pYISzhNl7pp1yqFDAGwpg1uNcDfbqwAN-_yW6meXzbuPGovesavpNKE-h0kHOXuKv7o-RLlSrwWroRihlbs1jyf8zmisiRnw3HJsO-J-I5xBwqLvzrB-fve50C7liwohJ5QzZWeaMWtjwFaV-q2NWY=)\nannounces that a class action lawsuit has been filed against Capricor\nTherapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Capricor Therapeutics securities, you are encouraged to\nobtain additional information by visiting:\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit.\n\nKey Details of the Capricor Therapeutics ($CAPR) Class Action:\n* Lead Plaintiff Deadline: September 28, 2026\n* Lawsuit Allegations: Securities fraud alleging Capricor made false\nstatements concerning Deramiocel and the integrity of the clinical data\nsupporting its Biologics License Application.\n* Largest Alleged Stock Drop: July 27, 2026 – 64.5% Stock Drop\n* Court: U.S. District Court for the Southern District of California\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/capricor-class-action-lawsuit) to discuss your\nrights\nInvestors have until September 28, 2026 to ask the Court to be appointed to\nlead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Capricor securities. The class action is pending in the U.S. District Court\nfor the Southern District of California. It is captioned Nkamga v. Capricor\nTherapeutics, Inc. et al., No. 26-cv-04385.\n\nWhy is Capricor Being Sued for Securities Fraud?\n\nCapricor is a biotechnology company focused on developing cell and\nexosome-based therapeutics for rare diseases. Its lead product candidate,\nDeramiocel, is an investigational cell therapy being developed for Duchenne\nmuscular dystrophy.\n\nAccording to the complaint, Capricor submitted a Biologics License Application\nto the FDA for Deramiocel in late 2024. In July 2025, the FDA issued a\nComplete Response Letter stating that the application did not meet the\nstatutory requirement for substantial evidence of effectiveness and that\nadditional clinical data was needed.\n\nAs alleged, Capricor failed to disclose that it adopted changes to the\npre-specified statistical analysis plan used to analyze clinical data for\nDeramiocel and that the FDA had not agreed to those changes before Capricor\nresubmitted the Deramiocel BLA.\n\nWhy did Capricor’s Stock Drop? \n\nOn July 27, 2026, the FDA released briefing documents ahead of an advisory\ncommittee meeting concerning Deramiocel. The FDA briefing documents reportedly\nraised concerns about post-hoc changes to Capricor’s statistical analysis\nplan, including changes to the methodology for calculating the primary\nendpoint, PUL 2.0, shortly before the database was unlocked and unblinded.\nThis news caused the price of Capricor stock to decline $12.70 per share, or\n64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per\nshare on July 27, 2026, the following trading day.\n\nOn July 29, 2026, the FDA advisory committee met to discuss the Deramiocel\nBLA. The next day, a medical news website named Medscape reported that in a\nnon-binding 9-3 vote, the panel concluded that available evidence did not\nsupport the efficacy of Deramiocel for treating DMD-associated cardiomyopathy.\nOn this news, Capricor’s stock dropped $2.38 per share, or 36%, from a\nclosing price of $6.57 per share on July 29, 2026, to $4.19 per share on July\n30, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Capricor Therapeutics securities, you may have legal\noptions and are encouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3k6hRW","title":"Investor Notice: Capricor Therapeutics (NASDAQ:CAPR) Accused of Misleading Investors in Securities Fraud Class Action – Contact BFA Law if You Lost Money","author":"Globe Newswire","ticker":"CAPR","created":"2026-08-28T10:46:00.134Z","tickers":["CAPR"],"exchange":"NASDAQ","article_body":"NEW YORK, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm\nBleichmar Fonti & Auld LLP\n(https://www.globenewswire.com/Tracker?data=lFM_FrqgjWD9sSl_oHO13pYISzhNl7pp1yqFDAGwpg1uNcDfbqwAN-_yW6meXzbuPGovesavpNKE-h0kHOXuKv7o-RLlSrwWroRihlbs1jyf8zmisiRnw3HJsO-J-I5xBwqLvzrB-fve50C7liwohJ5QzZWeaMWtjwFaV-q2NWY=)\nannounces that a class action lawsuit has been filed against Capricor\nTherapeutics, Inc. (NASDAQ:CAPR) and certain of the company’s senior\nexecutives for securities fraud after its significant stock drop resulting\nfrom potential violations of the federal securities laws.\n\nIf you invested in Capricor Therapeutics securities, you are encouraged to\nobtain additional information by visiting:\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit.\n\nKey Details of the Capricor Therapeutics ($CAPR) Class Action:\n* Lead Plaintiff Deadline: September 28, 2026\n* Lawsuit Allegations: Securities fraud alleging Capricor made false\nstatements concerning Deramiocel and the integrity of the clinical data\nsupporting its Biologics License Application.\n* Largest Alleged Stock Drop: July 27, 2026 – 64.5% Stock Drop\n* Court: U.S. District Court for the Southern District of California\n* Action: Contact BFA Law\n(https://www.bfalaw.com/cases/capricor-class-action-lawsuit) to discuss your\nrights\nInvestors have until September 28, 2026 to ask the Court to be appointed to\nlead the case. The complaint asserts securities fraud claims under Sections\n10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors\nin Capricor securities. The class action is pending in the U.S. District Court\nfor the Southern District of California. It is captioned Nkamga v. Capricor\nTherapeutics, Inc. et al., No. 26-cv-04385.\n\nWhy is Capricor Being Sued for Securities Fraud?\n\nCapricor is a biotechnology company focused on developing cell and\nexosome-based therapeutics for rare diseases. Its lead product candidate,\nDeramiocel, is an investigational cell therapy being developed for Duchenne\nmuscular dystrophy.\n\nAccording to the complaint, Capricor submitted a Biologics License Application\nto the FDA for Deramiocel in late 2024. In July 2025, the FDA issued a\nComplete Response Letter stating that the application did not meet the\nstatutory requirement for substantial evidence of effectiveness and that\nadditional clinical data was needed.\n\nAs alleged, Capricor failed to disclose that it adopted changes to the\npre-specified statistical analysis plan used to analyze clinical data for\nDeramiocel and that the FDA had not agreed to those changes before Capricor\nresubmitted the Deramiocel BLA.\n\nWhy did Capricor’s Stock Drop? \n\nOn July 27, 2026, the FDA released briefing documents ahead of an advisory\ncommittee meeting concerning Deramiocel. The FDA briefing documents reportedly\nraised concerns about post-hoc changes to Capricor’s statistical analysis\nplan, including changes to the methodology for calculating the primary\nendpoint, PUL 2.0, shortly before the database was unlocked and unblinded.\nThis news caused the price of Capricor stock to decline $12.70 per share, or\n64.5%, from a closing price of $19.70 per share on July 24, 2026, to $7.00 per\nshare on July 27, 2026, the following trading day.\n\nOn July 29, 2026, the FDA advisory committee met to discuss the Deramiocel\nBLA. The next day, a medical news website named Medscape reported that in a\nnon-binding 9-3 vote, the panel concluded that available evidence did not\nsupport the efficacy of Deramiocel for treating DMD-associated cardiomyopathy.\nOn this news, Capricor’s stock dropped $2.38 per share, or 36%, from a\nclosing price of $6.57 per share on July 29, 2026, to $4.19 per share on July\n30, 2026.\n\nClick here for more information:\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit.\n\nWhat Can You Do?\n\nIf you invested in Capricor Therapeutics securities, you may have legal\noptions and are encouraged to submit your information to the firm.\n\nAll representation is on a contingency fee basis; there is no cost to you.\nShareholders are not responsible for any court costs or expenses of\nlitigation. The firm will seek court approval for any potential fees and\nexpenses.\n\nSubmit your information by visiting:\n\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit\n\nOr contact:\n\nAdam McCall\nadam@bfalaw.com\n212.789.3619\n\nWhy Bleichmar Fonti & Auld LLP?\n\nBFA is a leading international law firm representing plaintiffs in securities\nclass actions and shareholder litigation. It has been named a top plaintiff\nlaw firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have\nbeen named “Elite Trial Lawyers” by the National Law Journal,\n“Litigation Stars” by Benchmark Litigation, among the top “500 Leading\nPlaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’\nBar” by Law360 and “SuperLawyers” by Thomson Reuters.\n\nMost recently, The Legal 500 awarded BFA the most client satisfaction\naccolades of any plaintiff’s securities litigation law firm, with clients\nnoting: “[t]here is no better service provider in the practice area,”\n“[t]he interest of the client is always front and center,” and “[t]here\nisn’t a better firm in this space.” One testimonial described the firm as\n“nimble and entrepreneurial,” with a “relentless focus on adding value\nfor clients.”\n\nAmong its recent notable successes, BFA recovered over $900 million in value\nfrom Tesla, Inc.’s Board of Directors, as well as $420 million from Teva\nPharmaceutical Ind. Ltd.\n\nFor more information about BFA and its attorneys, please visit\nhttps://www.bfalaw.com.\n\nhttps://www.bfalaw.com/cases/capricor-class-action-lawsuit\n\nAttorney advertising. Past results do not guarantee future outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/44a256cf-d470-4d8a-af6b-dbb1b5bbb11e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-28T10:46:00.17940972Z","server_sent_at_ms":1787913960179},"received_at":"2026-08-28T10:46:00.237Z","source_url":null},"analysis":{"id":"119092","press_release_id":"130183","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Capricor Therapeutics alleging securities fraud related to the integrity of clinical data for Deramiocel.\n\nThe lawsuit follows a 64.5% stock decline on July 27, 2026, after FDA briefing documents raised concerns about post-hoc changes to the statistical analysis plan.\n\nInvestors have until September 28, 2026, to seek appointment as lead plaintiff in the case pending in the Southern District of California.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"stock_drop_percent":"64.5%","lead_plaintiff_deadline":"September 28, 2026"}},"quotedText":"Investors have until September 28, 2026 to ask the Court to be appointed to lead the case.","namedEntities":{"people":[{"name":"Adam McCall","role":"Attorney"}],"products":["Deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$12.70 per share","context":"stock price decline on July 27, 2026"},{"amount":"$19.70 per share","context":"closing price on July 24, 2026"},{"amount":"$7.00 per share","context":"closing price on July 27, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bleichmar Fonti & Auld LLP. No new disclosure from the issuer; this is a standard lead plaintiff deadline reminder for an existing lawsuit."},"tickerRelevance":{"others":[],"primary":"CAPR"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bleichmar Fonti & Auld LLP announced a class action lawsuit against Capricor Therapeutics alleging securities fraud related to the integrity of clinical data for Deramiocel.\n\nThe lawsuit follows a 64.5% stock decline on July 27, 2026, after FDA briefing documents raised concerns about post-hoc changes to the statistical analysis plan.\n\nInvestors have until September 28, 2026, to seek appointment as lead plaintiff in the case pending in the Southern District of California.","key_figures":{"customDimensions":{"stock_drop_percent":"64.5%","lead_plaintiff_deadline":"September 28, 2026"}},"named_entities":{"people":[{"name":"Adam McCall","role":"Attorney"}],"products":["Deramiocel"],"companies":[{"name":"Capricor Therapeutics, Inc.","ticker":"CAPR","relationship":"defendant"},{"name":"Bleichmar Fonti & Auld LLP","relationship":"plaintiff law firm"},{"name":"U.S. Food and Drug Administration","relationship":"regulatory body"}],"dollarAmounts":[{"amount":"$12.70 per share","context":"stock price decline on July 27, 2026"},{"amount":"$19.70 per share","context":"closing price on July 24, 2026"},{"amount":"$7.00 per share","context":"closing price on July 27, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-28T10:47:35.647Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":95391,"modelName":"glm-4.7"}}